113 related articles for article (PubMed ID: 35940182)
1. Psychometric properties of the French Hot Flash Related Daily Interference Scale (HFRDIS).
Cavadias I; Rouzier R; Milder M; Bonneau C; Mullaert J; Hequet D
Climacteric; 2023 Jun; 26(3):1-4. PubMed ID: 35940182
[TBL] [Abstract][Full Text] [Related]
2. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer.
Carpenter JS
J Pain Symptom Manage; 2001 Dec; 22(6):979-89. PubMed ID: 11738160
[TBL] [Abstract][Full Text] [Related]
3. Validity, cut-points, and minimally important differences for two hot flash-related daily interference scales.
Carpenter JS; Bakoyannis G; Otte JL; Chen CX; Rand KL; Woods N; Newton K; Joffe H; Manson JE; Freeman EW; Guthrie KA
Menopause; 2017 Aug; 24(8):877-885. PubMed ID: 28509814
[TBL] [Abstract][Full Text] [Related]
4. Increased hot flash severity and related interference in perimenopausal human immunodeficiency virus-infected women.
Looby SE; Shifren J; Corless I; Rope A; Pedersen MC; Joffe H; Grinspoon S
Menopause; 2014 Apr; 21(4):403-9. PubMed ID: 23820600
[TBL] [Abstract][Full Text] [Related]
5. Psychometric properties of the Menopause Specific Quality of Life questionnaire among Thai women with a history of breast cancer.
Phligbua W; Smith EML; Barton DL
Eur J Oncol Nurs; 2018 Oct; 36():75-81. PubMed ID: 30322513
[TBL] [Abstract][Full Text] [Related]
6. Cross-cultural validation of the French version of the Lymphedema Functioning, Disability and Health Questionnaire for Upper Limb Lymphedema (Lymph-ICF-UL).
De Vrieze T; Frippiat J; Deltombe T; Gebruers N; Tjalma WAA; Nevelsteen I; Thomis S; Vandermeeren L; Belgrado JP; De Groef A; Devoogdt N
Disabil Rehabil; 2021 Sep; 43(19):2797-2804. PubMed ID: 31990592
[TBL] [Abstract][Full Text] [Related]
7. A comparison of three outcome measures of the impact of vasomotor symptoms on women's lives.
Hunter MS; Nuttall J; Fenlon D
Climacteric; 2019 Aug; 22(4):419-423. PubMed ID: 30905177
[No Abstract] [Full Text] [Related]
8. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.
Stearns V; Isaacs C; Rowland J; Crawford J; Ellis MJ; Kramer R; Lawrence W; Hanfelt JJ; Hayes DF
Ann Oncol; 2000 Jan; 11(1):17-22. PubMed ID: 10690382
[TBL] [Abstract][Full Text] [Related]
9. The effect of oral evening primrose oil on menopausal hot flashes: a randomized clinical trial.
Farzaneh F; Fatehi S; Sohrabi MR; Alizadeh K
Arch Gynecol Obstet; 2013 Nov; 288(5):1075-9. PubMed ID: 23625331
[TBL] [Abstract][Full Text] [Related]
10. Hot flashes and related outcomes in breast cancer survivors and matched comparison women.
Carpenter JS; Johnson D; Wagner L; Andrykowski M
Oncol Nurs Forum; 2002 Apr; 29(3):E16-25. PubMed ID: 11979290
[TBL] [Abstract][Full Text] [Related]
11. French translation and validation of the "Anterior Knee Pain Scale" (AKPS).
Buckinx F; Bornheim S; Remy G; Van Beveren J; Reginster J; Bruyère O; Dardenne N; Kaux JF
Disabil Rehabil; 2019 May; 41(9):1089-1094. PubMed ID: 29264931
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition.
Freeman MP; Hirschberg AM; Wang B; Petrillo LF; Connors S; Regan S; Joffe H; Cohen LS
Maturitas; 2013 Jun; 75(2):170-4. PubMed ID: 23602542
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial.
Kashani L; Esalatmanesh S; Eftekhari F; Salimi S; Foroughifar T; Etesam F; Safiaghdam H; Moazen-Zadeh E; Akhondzadeh S
Arch Gynecol Obstet; 2018 Mar; 297(3):717-724. PubMed ID: 29332222
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a non-hormonal treatment, BRN-01, on menopausal hot flashes: a multicenter, randomized, double-blind, placebo-controlled trial.
Colau JC; Vincent S; Marijnen P; Allaert FA
Drugs R D; 2012 Sep; 12(3):107-19. PubMed ID: 22852580
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
[TBL] [Abstract][Full Text] [Related]
16. Cross-cultural adaptation, translation, and validation of the functional assessment scale for acute hamstring injuries (FASH) questionnaire for French-speaking patients.
Locquet M; Willems T; Specque C; Beaudart C; Bruyère O; Van Beveren J; Dardenne N; Reginster JY; Kaux JF
Disabil Rehabil; 2020 Jul; 42(14):2076-2082. PubMed ID: 30669878
[No Abstract] [Full Text] [Related]
17. Validation of the French translation-adaptation of the impact of cancer questionnaire version 2 (IOCv2) in a breast cancer survivor population.
Blanchin M; Dauchy S; Cano A; Brédart A; Aaronson NK; Hardouin JB
Health Qual Life Outcomes; 2015 Jul; 13():110. PubMed ID: 26220672
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors.
Elkins G; Marcus J; Stearns V; Perfect M; Rajab MH; Ruud C; Palamara L; Keith T
J Clin Oncol; 2008 Nov; 26(31):5022-6. PubMed ID: 18809612
[TBL] [Abstract][Full Text] [Related]
19. Quality of life after pulmonary embolism: validation of the French version of the PEmb-QoL questionnaire.
Rochat M; Méan M; Limacher A; Hugli O; Klok FA; Cohn DM; Aujesky D
Health Qual Life Outcomes; 2014 Dec; 12():174. PubMed ID: 25464821
[TBL] [Abstract][Full Text] [Related]
20. Cross-cultural adaptation into French and validation of the SCAR-Q questionnaire.
Radulesco T; Mancini J; Penicaud M; Grob JJ; Richard MA; Dessi P; Malissen N; Michel J
Qual Life Res; 2021 Apr; 30(4):1225-1231. PubMed ID: 33389488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
